Welcome to our dedicated page for Amgen SEC filings (Ticker: AMGN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Amgen Inc. SEC filings document the regulatory record for a Nasdaq-listed biotechnology company with common stock and registered debt securities. Its 8-K reports cover quarterly and annual earnings releases, Regulation G reconciliations for non-GAAP measures, free cash flow disclosures, material definitive agreements, executive leadership changes and capital markets transactions.
The company's proxy materials describe annual meeting matters, board governance, executive compensation and stockholder voting procedures. Other filings address senior note offerings under registration statements and indentures, Nasdaq listing and registration matters for debt securities, and formal exhibits that define the terms of financing, governance and corporate disclosure events.
Amgen Inc. executive Peter H. Griffith, EVP & CFO, reported a routine tax-related share disposition. On the reported date, 556 shares of Amgen common stock were surrendered at $331.11 per share to cover tax obligations, a non-market "tax-withholding disposition" rather than an open-market sale.
Following this transaction, Griffith directly held 50,150 shares of Amgen common stock. A footnote explains that his holdings include Dividend Equivalents credited to unvested Restricted Stock Units under Amgen’s equity incentive plan, which are paid in shares as those awards vest.
Amgen Inc. executive Jonathan P. Graham reported a small tax-related share disposition. On the transaction date, 499 shares of Amgen common stock were withheld at $331.11 per share to cover exercise price or tax liability, a routine administrative event rather than an open-market sale.
After this tax-withholding disposition, Graham directly held 39,712 Amgen shares. His holdings include 311 Dividend Equivalents granted under Amgen’s equity incentive plan, which are tied to unvested Restricted Stock Units and pay out in shares on a one-to-one basis as those awards vest.
Amgen Inc. executive vice president of Global Commercial Operations Murdo Gordon reported a small stock transaction related to taxes. On a Form 4, he showed a tax-withholding disposition of 615 shares of Amgen common stock at $331.11 per share, a mechanistic step to cover obligations associated with equity compensation rather than an open-market sale. After this transaction, he directly holds 51,222 shares of Amgen common stock. The reported holdings include 386 Dividend Equivalents tied to unvested restricted stock units under Amgen’s equity incentive plan, which will be paid out in shares as those units vest.
Amgen Inc. Chairman, CEO and President Robert A. Bradway reported a routine tax-withholding transaction in company stock. On 2026-05-07, 2,079 shares of Amgen common stock were withheld at $331.11 per share to satisfy tax obligations, not as an open-market sale.
Following this withholding, Bradway directly owns 505,160 shares of Amgen common stock. He also reports indirect holdings through related parties, including shares held by his spouse and in spousal GRAT and GRAT vehicles, reflecting additional indirect economic exposure to Amgen stock.
Amgen Inc. EVP of Research and Development James E. Bradner reported a small tax-related share disposition. On the reported date, 446 shares of common stock were withheld at $331.11 per share to satisfy tax obligations, a non-market transaction classified as a tax-withholding disposition.
After this event, Bradner directly held 30,016 Amgen shares. The reported holdings include 1,273 dividend equivalents tied to unvested restricted stock units that will pay out in Amgen common stock as they vest, along with cash for any fractional share amounts.
Amgen Inc. executive James E. Bradner reported routine equity compensation activity. On May 5, 2026, he acquired 3,337 Restricted Stock Units (RSUs) at $0.00 per share, which vest in four equal annual installments of 25% each starting on May 5, 2027. These shares include 1,332 Dividend Equivalents (DEs) that will be paid in common stock following the same vesting schedule. He was also granted 21,773 non-qualified stock options with a $329.59 exercise price, vesting 25% annually from May 5, 2027 and expiring on May 5, 2036. On May 6, 2026, 407 shares of common stock were disposed of at $329.59 per share to cover tax obligations, a non-market tax-withholding disposition. After these transactions, Bradner directly holds 30,462 shares of Amgen common stock.
Amgen Inc. Chairman, CEO and President Robert A. Bradway reported routine equity compensation and related tax withholding. On May 5, 2026, he received 12,136 Restricted Stock Units (RSUs) at $0.00 per share and 79,176 non-qualified stock options with a $329.59 exercise price, all granted under Amgen’s Equity Incentive Plan.
The RSUs and options each vest in four equal annual installments of 25% starting on May 5, 2027, with vested RSUs settled in common shares and the options exercisable through May 5, 2036. A separate F-code transaction on May 6, 2026 reflects 1,702 shares used to satisfy tax obligations at $329.59 per share, not an open-market sale. After these transactions, Bradway directly holds 507,239 common shares, in addition to indirect holdings by his spouse and related GRATs.
Amgen executive Matthew C. Busch, VP Finance & CAO, reported routine equity compensation grants and related tax withholding. He received 455 shares of common stock as Restricted Stock Units, including 45 Dividend Equivalents, under Amgen’s Equity Incentive Plan. These RSUs vest in four equal 25% installments starting on 5/5/2027 and are settled in common shares.
Busch also received 2,969 non-qualified stock options with a $329.59 exercise price, vesting 25% annually from 5/5/2027 until expiration on 5/5/2036. To cover tax obligations, 50 shares of common stock were disposed of at $329.59 per share as a tax-withholding transaction, not an open-market sale. After these transactions, he directly holds 4,385 common shares.
Amgen EVP Murdo Gordon reported new equity awards and a small tax-related share withholding. On May 5, 2026, he received 3,640 Restricted Stock Units (RSUs) that vest in four equal annual installments of 25% starting on May 5, 2027, and will be settled in common shares. These RSUs include 458 Dividend Equivalents credited under Amgen’s Equity Incentive Plan. He was also granted 23,752 non-qualified stock options with a $329.59 exercise price, vesting 25% annually from May 5, 2027, and expiring on May 5, 2036. On May 6, 2026, 502 shares of common stock were disposed of at $329.59 per share to satisfy tax obligations, a non-market "F" code withholding. After these transactions, Gordon directly holds 51,837 Amgen common shares.
Amgen Inc. executive vice president and general counsel Jonathan P. Graham reported routine equity compensation changes. On May 5, 2026, he received 2,609 shares of common stock at no cost as a grant, increasing his direct holdings to 40,619 shares. The same day, he was granted 17,022 non-qualified stock options with an exercise price of $329.59 per share, exercisable in four equal annual installments starting May 5, 2027 and expiring in 2036. These options relate to an equal number of underlying common shares. On May 6, 2026, 408 shares were disposed of at $329.59 per share to satisfy tax obligations, leaving him with 40,211 shares held directly. The restricted stock units and options vest in four annual installments of 25% each beginning in 2027, and vested RSUs and related dividend equivalents will be settled in common shares on a one-to-one basis.